The Recordati pharmaceutical group is off to a good start to 2012, which in the first three months of the year recorded a net profit of 33,8 million euro, up 7,5% compared to the same period of 2011. Operating profit also grew by 7,5%, reaching 47,6 million. Consolidated revenues rose 11% to $219,6 million.
Recordati therefore confirmed the positive estimates for the whole of 2012: “The group's business – reads the press release – continued as expected in April and for the full year 2012 it is expected to achieve revenues between 810 and 830 million, an operating profit between 160 and 170 million and a net profit between 115 and 120 million”.
The net financial position as at 31 March 2012 showed a net debt of 54,1 million. Shareholders' equity increased further and amounted to 630,2 million.
